COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1201
https://www.valueinhealthjournal.com/article/S1098-3015(15)03277-5/fulltext
Title : COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03277-5&doi=10.1016/j.jval.2015.09.1201
First page : A462
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 699
Categories :
Tags :
Regions :
ViH Article Tags :